Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (221-230 of 282) with videos related to

Pageof 29
Sort By:
The Lancet. Healthy Longevity|December 6, 2021
Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational studyAmy C Justice, Kirsha S Gordon, Jonathon Romero, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
The Journal of Antimicrobial Chemotherapy|August 23, 2014
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populationsDaniel F Carr, Mas Chaponda, Elena M Cornejo Castro, et al.
Clinical Pharmacology and Therapeutics|February 1, 2025
Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation StudyAmedeo De Nicolò, Alice Palermiti, Henry Mugerwa, et al.
Trials|June 21, 2020
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trialGareth Griffiths, Richard Fitzgerald, Thomas Jaki, et al.
Trials|November 20, 2020
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trialCatherine R Hanna, Kevin G Blyth, Glenn Burley, et al.
The Journal of Antimicrobial Chemotherapy|February 10, 2012
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Violet Okaba-Kayom, et al.
HIV Medicine|June 2, 2019
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019Margherita Bracchi, Clare van Halsema, Frank Post, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2019
Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based StudyBeatriz López-Centeno, Carlos Badenes-Olmedo, Ángel Mataix-Sanjuan, et al.
Pageof 29

Showing results (221-230 of 282) with videos related to

Sort By:
Pageof 29
The Lancet. Healthy Longevity|December 6, 2021
Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational studyAmy C Justice, Kirsha S Gordon, Jonathon Romero, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
The Journal of Antimicrobial Chemotherapy|August 23, 2014
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populationsDaniel F Carr, Mas Chaponda, Elena M Cornejo Castro, et al.
Clinical Pharmacology and Therapeutics|February 1, 2025
Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation StudyAmedeo De Nicolò, Alice Palermiti, Henry Mugerwa, et al.
Trials|June 21, 2020
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trialGareth Griffiths, Richard Fitzgerald, Thomas Jaki, et al.
Trials|November 20, 2020
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trialCatherine R Hanna, Kevin G Blyth, Glenn Burley, et al.
The Journal of Antimicrobial Chemotherapy|February 10, 2012
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Violet Okaba-Kayom, et al.
HIV Medicine|June 2, 2019
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019Margherita Bracchi, Clare van Halsema, Frank Post, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2019
Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based StudyBeatriz López-Centeno, Carlos Badenes-Olmedo, Ángel Mataix-Sanjuan, et al.
Pageof 29